**Spatially resolved deconvolution of the fibrotic niche in lung fibrosis**

# Michael Eyres1\*, Joseph Bell2,3\*, Elizabeth R. Davies2,3,5, Aurelie Fabre4, Aiman Alzetani3,6, Sanjay Jogai3,6, Ben G. Marshall3,6, David A. Johnston7, Zijian Xu5,8, Sophie V. Fletcher3,6, Yihua Wang3,5,8, Gayle Marshall1, Donna E. Davies2,3,8, Emily Offer1#, Mark G. Jones2,3,8,9#

1Medicines Discovery Catapult, Alderley Park, Cheshire, UK

2Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, UK.

3NIHR Southampton Biomedical Research Centre, University Hospital Southampton, UK.

4Department of Histopathology, St. Vincent's University Hospital & UCD School of Medicine, University College Dublin, Ireland

5Biological Sciences, Faculty of Environmental and Life Sciences, University of Southampton, UK.

6University Hospital Southampton, Southampton, UK.

7Biomedical Imaging Unit, Faculty of Medicine, University of Southampton, UK

8Institute for Life Sciences, University of Southampton, UK.

9Lead contact

\*These authors contributed equally to this work.

#Senior authors contributed equally to this work

Correspondence to:

Dr Mark Jones, Mark.Jones@soton.ac.uk.

**Summary**

A defining pathological feature of human lung fibrosis is localised tissue heterogeneity which challenges the interpretation of transcriptomic studies that typically lose spatial information. Here we investigate spatial gene expression in diagnostic tissue using digital profiling technology. We identify distinct, region-specific gene expression signatures as well as shared gene signatures. By integration with single cell data, we spatially map the cellular composition within and distant to the fibrotic niche, demonstrating discrete changes in homeostatic and pathologic cell populations even in morphologically preserved lung, whilst through ligand-receptor analysis we investigate cellular cross-talk within the fibrotic niche. We confirm findings through bioinformatic, tissue and *in vitro* analyses, identifying that loss of *NFKBIZ* in alveolar epithelial cells dysregulates the TGFβ/IL-6 signalling axis which may impair homeostatic responses to environmental stress. Thus, spatially resolved deconvolution advances understanding of cell composition and microenvironment in human lung fibrogenesis.

**Keywords:** Fibrosis; spatial transcriptomics; Cellular deconvolution; Lung; Alveolar epithelial cell homeostasis

# **Introduction**

Idiopathic pulmonary fibrosis (IPF) is the prototypic progressive fibrotic lung disease with an average life expectancy of 3-5 years after diagnosis. Treatment options remain limited and so better understanding of disease pathogenesis remains an area of intense investigation. Idiopathic by definition, the aetiology of IPF remains uncertain. Historically it was hypothesised that chronic inflammation resulting from lung injury progressed to tissue damage and fibrosis. In recent years significant advances have been made in the understanding of human IPF disease pathogenesis. This, together with the recognised absence of benefit, or even potential harm, of immunosuppressive therapies in patients with IPF has supported a shift from this paradigm. Current opinion is that progressive fibrosis is a consequence of multiple interacting genetic and environmental risk factors, with repetitive local micro-injuries to ageing alveolar epithelium playing a central role (Richeldi et al., 2017).

Whilst transcriptomic studies with homogenised IPF lung tissue have provided significant insights into IPF pathogenesis, identifying altered expression of numerous genes and aberrant activation of multiple signalling pathways (DePianto et al., 2015; Yang et al., 2013), the core determinants underlying the initiation and progression of fibrosis remain poorly understood (Mehal et al., 2011; Selman et al., 2008; Selman and Pardo, 2002; Vukmirovic and Kaminski, 2018). Disease heterogeneity within the lung poses a particular challenge to interpretation of such transcriptomic studies in IPF. Tissue shows areas of marked fibrosis adjacent to normal appearing lung as well as architectural distortion and the presence of fibroblastic foci, enigmatic regions pathognomonic of the disease, representing sites of active fibrogenesis (King Jr et al., 2017; Raghu et al., 2006; Richeldi et al., 2017).

Analysis of human IPF pathogenesis studies has focussed on mesenchymal and epithelial cell populations. Although dysregulation of multiple cell types has been proposed, the cross-talk between cell populations remains poorly understood. In addition, the presence of aggregates of infiltrating immune cells close to (but not always within) sites of active fibrosis is well described (Nuovo et al., 2012). These immune cells appear unable to penetrate the stroma of fibroblastic foci in a phenomenon similar to that observed in some fibrotic cancers, for example pancreatic tumours (R. Liu et al., 2021). In the latter setting, there is increasing evidence that the cross-talk between the tumour cells, cancer associated fibroblasts, and immune cells may lead to immune suppression and contribute to determine tumour progression (Seager et al., 2017). Thus, in human lung fibrosis there is a need to better understand the interplay among subpopulations of mesenchymal cells, epithelial cells, immune cells, and extracellular matrix components which cooperatively form the fibrosis-specific microenvironment (i.e., the fibrotic niche).

The recent application of single-cell RNA sequencing (scRNA-seq) approaches to IPF tissue has provided understanding of diverse aberrant cell populations. However a limitation of scRNA-Seq is that it does not permit spatial characterization of sequenced cells or the interactions between regions (Adams et al., 2020; Morse et al., 2019; Peyser et al., 2019; Reyfman et al., 2019; Tsukui et al., 2020; Xu et al., 2016), and both homogenised bulk IPF lung tissue and scRNA-Seq studies have typically been performed upon end-stage fibrotic lung tissue obtained at time of lung transplantation which may have less relevance for understanding of early disease processes. Spatial transcriptomics provides the capability to circumvent such issues by generating gene expression data for specific, well-defined regions of interest (ROIs) within tissue sections. The recently established digital spatial profiling (DSP) methodology enables quantitative, multiplex analysis of mRNAs in spatially defined regions within formalin-fixed paraffin embedded tissues (Merritt et al., 2020), so offering the possibility to investigate region specific gene expression profiles in tissue obtained at time of diagnosis.

Here, we investigated spatial gene expression in diagnostic IPF lung tissue using digital spatial profiling technology and confirmed our findings through bioinformatic, tissue and *in vitro* analyses. By integration with single cell data we spatially mapped the cellular composition within and distant to the fibrotic niche, and studied cellular cross-talk by performing an analysis of ligand–receptor interactions. Together these approaches demonstrate spatially resolved changes in homeostatic and pathologic cell populations, reduced inflammatory gene expression signatures including decreased innate immunity, and identify that loss of *NFKBIZ* in alveolar epithelial cells dysregulates the TGFβ/IL-6 signalling axis which may impair homeostatic responses to environmental stress in early disease.

# **Results**

## **Digital spatial gene expression profiling of human lung fibrosis tissue**

We characterized the mRNA expression within 66 morphologically distinct regions of interest (ROIs) (Figure 1) in diagnostic human IPF lung tissue and control lung tissue using digital spatial profiling (DSP) with the Nanostring GeoMx platform (Figure 1A). The tissue was interrogated using the GeoMx Cancer Transcriptome Atlas (CTA) mRNA assay of 1813 unique genes which encompasses cell biology, metabolic, microenvironment and immune response pathways. As DSP is non-destructive following GeoMx analysis H&E staining was performed on the same tissue sections and region selection was reviewed by a histopathologist. Following this review 6 ROIs were excluded, therefore 60 ROIs were analysed (Table S1 and Table S2). ROIs analysed were fibroblastic foci (IPF-FF, n=10) and their adjacent alveolar septae (IPF-AAS, n=10), nearby immune infiltrates identified by CD45+ staining (IPF-IM, n=6), morphologically preserved alveolar septae distant from fibroblastic foci (IPF-DAS, n=10), and blood vessel walls containing smooth muscle (IPF-BV, n=6) (Figure 1B-E). In healthy control lung tissue selected ROIs were alveolar septae (CTRL-AS, n=12) and blood vessel walls containing smooth muscle (CTRL-BV, n=6) (Figure 1F-H). Applying an expression cut-off of 5% (i.e., genes expressed in >5% of samples), a total of 1113 genes out of 1813 in the CTA were selected for further analysis.

## **Distinct gene expression signatures in spatially resolved regions of lung tissue**

We firstly determined biologically plausible clustering of ROIs when visualised by t-stochastic nearest neighbour embedding (t-SNE) dimensional reduction plot (Figure 2A) and a Pearson correlation heatmap (Figure S1), identifying separation of different ROIs, with this most evident for immune infiltrates and fibroblastic foci. We confirmed enrichment of expected marker genes within ROIs (Figure 2B–2F) as well as differentially expressed genes across the dataset (Figure 2G). The highest expression of *PTPRC* (CD45), an immune marker, was identified in the immune infiltrate, *PECAM1* and *EPCAM* (endothelial and epithelial markers, respectively) within alveolar regions, *ACTA2* (alpha smooth muscle actin, a smooth muscle and myofibroblast marker) in the vessel walls and fibroblastic foci, and *MCAM* (expressed by cells constituting blood vessels) within blood vessel walls.

To visualize whole signalling pathways and cell processes that were activated or repressed within different regions of tissue we graphed (Figure 2H-K) normalised gene expression values grouped by gene sets (Table S3). Comparison of control and IPF alveolar septae ROIs identified enrichment of Wnt and PDGF signalling in IPF alveolar septae whilst there was suppression of TNF signalling (Figure H) and interferons (Figure 2I). Comparison of spatially related IPF ROIs (IPF adjacent alveolar septae, immune infiltrate and fibroblastic foci) showed enrichment of cell processes involving EMT, ECM and motility in fibroblastic foci and adjacent alveolar septae (Figure 2J), with signalling pathways including PDGF and TGFβ superfamily signalling enriched in fibroblast foci (Figure 2H). Within the vessels, ion transport and mitochondrial metabolism were increased (Figure 2J,K), while TNF signalling was decreased (Figure 2H).

Together these data confirm successful GeoMx digital spatial profiling, identifying biologically plausible differential expression changes within distinct regions of interest in normal and fibrotic lung tissue.

**Identification of spatially resolved changes in homeostatic and pathologic cell populations in lung fibrosis**

To investigate the cellular composition within each spatially defined ROI we used the spatial deconvolution methodology (Danaher et al., 2020), applying a signature matrix, generated from a single cell RNAseq dataset of 31 cell types derived from healthy and IPF lung tissue (Habermann et al., 2020) (Figure 3A). Alveolar septae contained predominantly ATI, ATII and endothelial cells (Figure 3B,C), immune infiltrates contained an array of different immune cell types, including B, T and plasma cells (Figure 3D), whilst fibroblastic foci contained multiple mesenchymal cell types (Figure 3E).

When comparing the cellular composition of alveolar septae in control tissue with those distant from- and adjacent to- sites of fibrosis, the proportion of Alveolar type I and II cells was not substantially different (Figure 3B, Figure S2A,B). However, basal cells and the recently proposed pathologic KRT5−/KRT17+ cell population were only identified within IPF tissue and their proportion increased from distant to adjacent alveolar septae (Figure 3B, Figure S2C-D).

We also observed an increase in the proportion of proliferating macrophages from control to distant alveolar septae to those adjacent to sites of fibrosis (Figure 3D, Figure S2E) whilst there was a reduction in endothelial cells in IPF alveolar septae with the reduction being greatest in septae close to fibroblastic foci (Figure 3C, Figure S2F). This might be explained by a decrease in expression of the endothelial mitogens, *EDN1* and *VEGF* isoforms in IPF alveolar septae (Figure S3A-D).

In contrast to the reduction identified in endothelial cells, there was a stepwise increase in myofibroblasts from healthy control alveolar septae to IPF distant alveolar septae to adjacent alveolar septae (Figure 3E, Figure S2G). Notably, *HAS1hi*fibroblasts (Figure 3E, Figure S2H), a recently proposed pathologic IPF fibroblast subtype (Habermann et al., 2020), were also identified within adjacent alveolar septae and fibroblastic foci whilst these cells were absent from all other areas. Conversely, PLIN2+ fibroblasts, a suggested homeostatic lipofibroblast-like cell type (Habermann et al., 2020), were present within control and IPF alveolar septae whilst being poorly represented in fibroblastic foci and IPF blood vessels (Figure 3E, Figure S2I). As expected, smooth muscle cells were the dominant cell type within blood vessel walls (Figure 3E, Figure S2J).

Together these data identify spatially discrete changes in homeostatic and pathologic cell populations in lung fibrosis and suggest that pathogenetic mechanisms may be active, even in morphologically preserved alveolar septae within IPF lung tissue.

**Enrichment of a bone morphogenesis signature within fibroblastic foci**

We next studied the differentially expressed genes enriched within fibroblastic foci (Figure 4A). Tenascin C (*TNC*), a gene encoding an ECM glycoprotein which is increased in response to tissue injury was upregulated in fibroblastic foci, but not within the alveolar septae ROIs (Figure 4B) as well as *CRABP2*, a retinol-binding protein whose expression has recently been associated with IPF disease progression (Figure 4C) (Ghandikota et al., 2022). We also noted that all regions of interest in IPF showed a generalised increase in the Hallmark glycolysis gene set (Figure S3I), and that this effect was greatest in fibroblastic foci which contained the largest proportion of myofibroblasts, cells which are known to switch to aerobic glycolysis in response to TGF-β (Xie et al., 2015),

We identified a significant increase in multiple fibrillar collagen genes including *COL1A2* in fibroblastic foci, as well as an enrichment of the collagen fibril organisation gene set (Figure 4D-E). In contrast, *COL4A3*, a basal lamina associated collagen, was not increased in IPF fibroblastic foci (Figure 4F). Fibrillar collagen genes were also increased in IPF alveolar septae: this expression progressively increased from morphologically preserved alveolar septae to those adjacent to fibroblastic foci. This observation is in keeping with the progressive increase in mesenchymal cell proportions identified in our spatial deconvolution analysis.

In addition to collagen fibril assembly, gene set variation analysis also identified a progressive upregulation of genes associated with bone morphogenesis (Figure 4G), with the expression of *PLOD2,* whichencodes the lysyl hydroxylase 2 (LH2) enzyme required for pyridinium-type collagen cross-linking that predominates within bone (Qi and Xu, 2018), also upregulated in fibroblastic foci (Figure 4H) as well as expression of *COMP* which encodes cartilage oligomeric matrix protein and is primarily expressed within cartilage (Song et al., 2003) (Figure 4I). Further supporting this bone-type pathology is the upregulation of Runt-related transcription factor 1 (*RUNX1*), a transcription factor associated with increased expression of factors associated with osteogenesis (Tang et al., 2021) (Figure 4J). Although *RUNX1* is also associated with control of blood cell development (Imperato et al., 2015, p. 1), we noted a relative paucity of haematopoietic cells in fibroblastic foci. Using RNA-ISH we confirmed high expression of *COL1A2*, *COMP*, and *CRABP2* within fibroblast foci (Figure 4K), with immunofluorescence staining identifying the expression of COMP and PLOD2 within fibroblast foci (Figure S3J),

**Ligand-receptor interactions within the fibrotic niche**

DSP enables the quantification of the gene transcripts within distinct adjacent regions in tissue that may contain different cell types, thereby providing the possibility to investigate spatially resolved intercellular communication within the fibrotic niche. To determine how alveolar septae and immune infiltrates may signal to fibroblastic foci we therefore performed an analysis of ligand–receptor interactions. We applied NicheNet (Browaeys et al., 2020), a computational method that predicts ligand–receptor interactions based on induction of downstream target genes (Figure 5A,B). This identified the potential for signalling from adjacent regions to upregulate genes expressed in fibroblastic foci, with predicted signalling from adjacent alveolar septae via BMP4, CCL2, CD24, HGF, SPP1, PLAU, and TGFβ1, and signalling from immune infiltrates via CD24, HMGB1, SPP1, and TGFβ1 (Figure 5C,D). Predicted target genes included numerous extracellular matrix related genes driven by expression of multiple receptors present in fibroblastic foci (Figure 5E-G). We additionally performed *in silico* ligand-receptor analysis using Cellinker (Zhang et al., 2021), confirming the potential for signalling from adjacent regions to fibroblast foci including via HMGB1, PLAU, and TGFβ1 (Figure S4).

SPP1 (osteopontin) was amongst the most highly expressed ligands in adjacent alveolar septae whilst HMGB1 and CD24 were amongst the most highly expressed ligands in immune infiltrates. While SPP1 has been reported to be expressed in epithelial cells (Ali et al., 2019), it is also expressed in proliferating macrophages (Morse et al., 2019), a cell population that we identified in the adjacent alveolar septae using spatial deconvolution analysis (Figure 3D). HMGB1 signalling from immune infiltrates to fibroblastic foci could contribute to the increased expression of fibrillar collagen and alpha smooth muscle actin genes in the fibroblastic foci, a process previously identified in skin fibrosis (Lee et al., 2018). Furthermore, HMGB1 has also been identified as a downstream effector of SPP1 signalling in fibrogenic liver injury (Arriazu et al., 2017), highlighting the potential of distinct cell types within the fibrotic niche to co-ordinately drive a fibrotic response.

**Innate and inflammatory signatures are dysregulated across tissue compartments in lung fibrosis**

We next investigated immune and inflammatory gene expression signatures. Initially, IPF-IM ROIs were interrogated and differentially expressed genes in these ROIs compared to all others were identified (Figure 6A,B). The IPF-IM ROIs show a clear lymphocyte gene expression signature, including several canonical B cell markers such as *CD48* and *MS4A1* (Membrane-Spanning 4A (CD20) (Figure 6C and 6D). GSVA of the IPF-IM ROIs also confirmed the presence of T cells, with the CD4 receptor binding GO term enriched in these ROIs (Figure 6E). While GSVA identified an adaptive immune response gene signature in IPF immune infiltrate ROIs, this signature was decreased in other IPF ROIs compared with control ROIs (Figure 6F). Furthermore, there was a downregulation of the acute inflammatory response genes and TNFA signalling via NF-κB gene sets in all fibrotic tissue ROIs when compared to healthy control ROIs (Figure 6G and 6H).

CXCR4, the receptor for the homeostatic chemokine CXCL12, was amongst the most significantly upregulated genes in IPF-IM ROIs (Figure 6I). In many solid cancers, expression of CXCL12 by cancer associated fibroblasts (CAFs) leads to the exclusion of T cells and we also found that fibroblastic foci were the main source of CXCL12 expression (Figure 6J), suggesting that this chemokine may function to exclude immune cells from the fibrotic niche in lung fibrosis. Using independent single cell RNA sequencing data we confirmed expression of CXCR4 in lymphocytes and myeloid cells (Figure S5A-C), while CXCL12 was expressed by mesenchymal cells (Figure S5D-F), consistent with a recent report identifying an increase in CD45+CXCR4+ cells within IPF tissue with strong CXCL12 expression within fibroblast foci (Jaffar et al., 2020).

Comparison of the gene signatures associated with IPF-BV compared to CTRL-BV ROI identified a number of genes and gene sets with differential expression, with latent TGFβ binding protein 1 (LTBP1) and IL11 receptor alpha (IL11RA) being upregulated in IPF blood vessels compared to control vessels (Figure S3E-F). In contrast, JUNB expression was downregulated in IPF-BV ROIs compared to CTRl-BV (Figure S3G). This was also accompanied by a downregulation of the Hallmark TNFα signalling via NFκB gene set (Figure S3H).

Together these data suggest that the IPF immune infiltrates consist predominantly of adaptive immune cells, especially B and T cells, consistent with the spatial deconvolution analysis and that a CXCL12/CXCR4 axis may contribute to immunosuppression around the fibrotic niche. There was also an overall decrease in inflammatory gene sets in IPF lung tissue compared to normal lung whereas IL11RA, a component of IL11/IL11RA/IL6ST signalling complex that is involved in the control of proliferation and/or differentiation of skeletogenic progenitor or other mesenchymal cells, was increased in IPF vascular smooth muscle.

**Suppression of Type 1 interferon responses**

Comparison of alveolar septae regions identified that there was a progressive increase in expression of gene sets associated with TGFβ and Wnt signalling from control alveolar septae to distant IPF alveolar septae to IPF alveolar septae adjacent to fibrotic lesions (Figure 7A and 7B) in addition to increased expression of fibrillar collagen genes (Figure 5 and Table S4A). There was also a significant decrease in the expression of the antioxidant enzyme superoxide dismutase 2 (SOD2) which we confirmed with RNA-ISH suggesting lack of ability of IPF tissue to respond to reactive oxygen species generation (Figure 7C and Figure S7A), as well as genes associated with the interferon alpha response (Figure 7D).

We hypothesised that the suppression in Type I IFN-regulated gene expression could be explained by the identified increased expression of TGFβ signalling pathways, as we and others have previously reported that TGFβ suppresses Type I IFN-regulated gene expression in airway epithelium (Bedke et al., 2012; Denney et al., 2018). To further investigate this potential mechanism we treated Alveolar Type 2 cells with TGFβ in the absence or presence of the synthetic TLR3 agonist, polyinosinic:polycytidylic acid (poly I:C) to mimic viral infection. We identified that TGFβ suppressed *IFNB1* expression as well as the interferon inducible genes, *MX1* and *viperin* (Figure S6A-C), consistent with the potential for TGF-β to suppress the innate immune response to viral infection.

## **Loss of *NFKBIZ* dysregulates the IL-6 axis**

We also identified downregulation of *NFKBIZ* and *GADD45B* within IPF alveolar septae (Figure 7E and 7F). These are key components of the interleukin 6 (IL6) signalling pathway (Liebermann and Hoffman, 2002; Yamamoto et al., 2004) and correspondingly we found that GO response to IL6 was downregulated in IPF ROIs (Figure 7G), as well as IL6 expression itself (Figure 7H). We confirmed suppression of these genes in a published bulk microarray dataset comparing IPF and normal lung tissue (Figure 7I-K). Reduced NFKBIZ expression in IPF alveolar septae was further validated by interrogation of a publicly available laser-capture-microdissection RNAseq dataset of IPF alveolar septae, confirming a reduction in the expression of *NFKBIZ, IL6* and *GADD45B* in IPF alveolar septae compared to control tissue (Figure 7L-N). While the protein product of *NFKBIZ*, IκBζ, can inhibit the activity of NF-κB, it can also activate the transcription of a set of genes associated with the overactivation of the immune system in psoriasis (Bertelsen et al., 2017). Consistent with loss of *NFKBIZ*, there was decreased expression of *CCL20*, *CHI3L1, IL8* and *DEFB4* within IPF alveolar septae (Figure S6D-G).

Analysing publicly available data within the Human Protein atlas (Uhlén et al., 2015) we confirmed basal *NFKBIZ* gene expression within lung cell populations especially Alveolar Type 2 cells and granulocytes (Figure S7B) as well as nuclear localisation of IκBζ within alveolar epithelial cells in healthy human lung tissue (Figure S7C). We therefore performed immunostaining of control and IPF lung tissue, identifying IκBζ expression within control alveolar epithelial cells and that this was reduced within IPF alveolar septae (Figure S7D), and confirming through RNA-ISH that *NFKBIZ* was expressed within Alveolar Type 2 cells identified by the cell marker surfactant protein C (SFTPC) (Figure 7O).

*NFKBIZ* is a primary response gene, induced rapidly in innate immune cells such as monocytes and macrophages in response to pathogen associated molecular patterns (PAMPs) such as the TLR4 agonist lipopolysaccharide (LPS) (Eto et al., 2003). However *NFKBIZ* has also been shown to have cell-specific roles (Ahn et al., 2019; Hörber et al., 2016; Miyake et al., 2010; Touma et al., 2011) and, to our knowledge, basal expression of *NFKBIZ* in alveolar epithelial cells and the consequences of reduced expression upon alveolar homeostasis have not previously been investigated.

Therefore, to investigate the impact of loss of *NFKBIZ* on responses of Alveolar Type 2 cells we used siRNA knockdown. IL-6 can be induced by proinflammatory cytokines, as well as by TGFb. Given that we observed downregulation of the acute inflammatory response genes in all fibrotic tissue ROIs whereas TGFb signalling was increased, we elected to investigate the importance of *NFKBIZ* for TGFb-induced IL-6 expression. *NFKBIZ* was constitutively expressed in ATII epithelial cells *in vitro* (Figure 7P), and following TGFβ treatment this was unaffected whereas expression of IL6 and GADD45B was increased (Figure 7Q-R). Silencing of *NFKBIZ* (Figure S7E) led to a suppression of TGFβ-induced IL-6 mRNA and protein expression (Figure 7S-T). This was associated with a suppression in *GADD45B* expression (Figure 7U) which lies downstream of IL-6 and is usually induced in response to cellular stress to regulate cell survival and apoptosis (Salvador et al., 2013). Thus, spatial transcriptomic analyses complemented by bioinformatic, tissue, and *in vitro* studies has identified that loss of *NFKBIZ* in alveolar epithelial cells dysregulates the TGFβ/IL-6 axis which may contribute to the susceptibility of IPF alveolar epithelial cells to environmental stress.

**DISCUSSION**

Lung tissue from IPF patients shows marked heterogeneity of pathological changes, which may relate to temporal and/or spatial differences in pathophysiological mechanisms. Here spatial transcriptomics has enabled more precise assessment of the microenvironment and cellular cross-talk in IPF lung tissue through improved understanding of the location of the gene expression signatures detected, identifying discrete changes in homeostatic and pathologic cell populations including loss of endothelial cells, the presence of myofibroblasts throughout IPF lung tissue as well as the presence of *HAS1hi*fibroblasts within fibroblast foci. There is evidence of co-ordination of multiple cellular compartments contributing to fibrogenesis and aberrant tissue responses through their spatial proximity. Together these data identify potential pathological mechanisms that may occur in early disease including loss of *NFKBIZ* in alveolar epithelial cells.

Application of digital spatial profiling technology to interrogate the fibrotic niche in human lung fibrosis identified that even morphologically preserved IPF alveolar septae had evidence of dysregulated gene expression and altered cell population proportions. This manifested as an increase in collagen gene expression compared to control alveolar septae, an increase in the proportion of myofibroblasts, the presence of pathologically-related epithelial cell populations which were absent from control lung, as well as a decrease in the proportion of endothelial cells. The decrease in endothelial cells was present in IPF alveolar septae irrespective of whether they were adjacent to fibroblastic foci or more distal and morphologically preserved, suggesting that endothelial dysregulation could be an important contributory factor in the early stages of alveolar dysfunction. Similar to epithelial cells, endothelial cells can undergo endothelial to mesenchymal transition (EndMT) (Jia et al., 2021), a process that has previously been associated with vascular loss and accumulation of mesenchymal cells in IPF (Gaikwad et al., 2020). This hypothesis is supported by our identification of an increase in myofibroblasts in IPF alveolar septae.

While the decline in the proportion of endothelial cells was not accompanied by an apparent decrease in the number of ATI and ATII alveolar epithelial cells, evidence of epithelial dysregulation was evident. In some alveolar septae adjacent to fibroblastic foci, we observed an increase in transitional ATII cells that have an intermediate phenotype between ATII and ATI cells (Aspal and Zemans, 2020). This enrichment may represent the need for epithelial renewal in IPF alveolar septae. However, we also found an increase in basal cells in alveolar septae closest to fibroblast foci and, as basal cells act as bronchial stem cells in lung injury, their invasion into alveolar epithelium suggests progressive loss of alveolar progenitor cells. This may lead to alveolar remodelling and bronchiolisation of the distal lung (Shaykhiev, 2019). Further evidence of perturbation of alveolar epithelial homeostasis within the fibrotic niche was provided by the appearance of *HAS1hi*fibroblasts as well as myofibroblasts and loss of lipofibroblast-like PLIN2-positive fibroblasts. In mice, lipofibroblasts support ATII cells, not only by providing lipid substrates for lung surfactant production, but also by maintaining the ATII stem cell niche (Kumar et al., 2014; X. Liu et al., 2021; McGowan and Torday, 1997; Xie et al., 2018; Zepp et al., 2017). Thus, our data suggest that loss of alveolar homeostasis involves dysregulation of multiple cell types. As spatially-resolved transcriptomic analyses allow the selection of ROIs within IPF lung tissue that are morphologically preserved, this approach can aid identification of early pathogenic mechanisms and provide insight into their temporal relationships.

The apparent inability of immune cells to penetrate the stiffened stroma surrounding fibroblastic foci (Nuovo et al., 2012), is similar to the microenvironment of many solid tumours in which immune cells are excluded by stromal fibrosis. This has been associated with several mechanisms involving mediators produced cancer associated fibroblasts (CAFs) including expression of CXCL12 which mediates T-cell exclusion from the tumour and resistance to immunotherapy via CXCR4 (Feig et al., 2013). The importance of this mechanism has been inferred in models of pancreatic and breast cancer in which inhibition of CXCR4 using a clinically approved inhibitor (AMD3100) increased intratumoural T-cell accumulation and response to checkpoint inhibition (Chen et al., 2019).Our identification within IPF tissue of high expression of CXCR4 in the immune infiltrate ROIs and the expression of CXCL12 within fibroblastic foci suggests a potentially similar immune exclusion mechanism in lung fibrosis. While AMD3100 has been tested in preclinical models of lung fibrosis, its prophylactic antifibrotic activity was attributed to prevention of CXCL12-mediated migration of circulating fibrocytes into the injured lung.

We identify a significant downregulation of pathways associated with innate immunity in IPF ROIs compared to control lung ROIs, with a marked downregulation of TNFα signalling via NFκB, downregulation of type I interferon responses and IL6-related gene expression. The absence of inflammatory gene signatures is consistent with the absence of benefit identified in clinical trials of immune-modulatory drugs in IPF (King et al., 2009; Raghu et al., 2008). Downregulation of interferon associated gene expression has previously been reported in cells isolated from the peripheral blood of patients with IPF (Huang et al., 2021), and we identified a suppression of Type I interferon innate immune responses in IPF lung tissue, confirming through in vitro studies that TGFβ was sufficient to suppress Type I IFN-regulated gene expression. This observation may be relevant to virus-induced exacerbations (Azadeh et al., 2017). Furthermore, patients with interstitial lung disease have been shown to be at increased risk of death from COVID-19 infection (Drake et al., 2020), and a recent study identified that people with chronic lung disease who are at increased risk of severe COVID-19 infection have evidence of altered immune and inflammatory gene expression, including dysregulation of type I interferon response genes (Bui et al., 2021).

Spatial transcriptomics enabled the identification of a pathway by which loss of *NFKBIZ* in alveolar epithelial cells may perturb the TGFβ/IL-6 axis to dysregulate alveolar homeostasis in IPF. We observed a decrease in IL6-related gene expression, with a significant decrease in *NFKBIZ* and *GADD45B* expression, as well as a decrease in gene sets associated with IL6 signalling and IL6 JAK-STAT signalling. IκBζ, the protein product of *NFKBIZ,* has been identified as a key regulator of IL6 gene expression, and *GADD45B* expression is induced by IL6 signalling (Liebermann and Hoffman, 2002; Yamamoto et al., 2004). We confirmed downregulation of IL6 signalling, as well as the downregulation of *IL6*, *NFKBIZ* and *GADD45B* in a large-scale transcriptomic study of IPF versus healthy lung tissue (Yang et al., 2013) as well as showing decreased expression of IκBζ in alveolar epithelial cells in IPF lung tissue. We further demonstrated the functional relevance of IκBζ in ATII cells by siRNA knockdown of NFKBIZ which suppressed induction of IL-6 in response to TGFβ. IL-6 is a pleiotropic cytokine that can have either proinflammatory or profibrotic effects. Thus, while blockade of IL-6 signalling attenuates pulmonary fibrosis (Le et al., 2014), IL-6 protects against oxidant-induced death of alveolar epithelial cells and it regulates surfactant homeostasis in ATII cells (Kida et al., 2005; Matsuzaki et al., 2008). While targeting the IL-6 pathway with monoclonal antibodies such as Tocilizumab has provided treatment benefit in a number of diseases including rheumatoid arthritis, its use is associated with an increased risk of non-infectious pulmonary complications, especially interstitial lung disease consistent with an important role for IL-6 in maintaining pulmonary homeostasis (Hadjinicolaou et al., 2011).

In conclusion, spatially resolved deconvolution analyses of diagnostic IPF lung tissue has provided insight into cell composition and microenvironment within and surrounding the fibrotic niche. This approach will support advances in human disease relevant models and therapeutic targeting.

**Limitations of the study**

It is widely accepted that lung fibrosis involves a complex interplay between multiple cell types including mesenchymal, epithelial, and immune cells, however areas of active fibrogenesis – the fibrotic niche – remain poorly understood. Our study enabled the selection of multiple defined regions of interest in spatial proximity within the fibrotic niche – fibroblast foci, adjacent alveolar septae, immune infiltrates. One limitation of our work is that gene expression profiling was limited to 1813 genes encompassing cell biology, metabolic, microenvironment and immune response pathways and so other gene expression profiles are not available. Whilst our approach enabled robust selection of morphologically distinct regions within the marked heterogeneity of human lung fibrosis tissue, a second limitation is that sampling of additional regions such as small airways was not undertaken and may further inform understanding of fibrogenesis. A third limitation of the study is that the spatial resolution was limited to the defined ROI and so did not provide RNA profiling at the single cell level (Merritt et al., 2020), with the gene signatures of multiple cell types included within each ROI. We therefore employed spatial deconvolution methodology to further investigate cellular composition. Although these data provide a useful approximation of cell types within ROIs, integration within alternative approaches would be complementary in future work to further investigate the RNA profiles of single cells within the fibrotic niche. Finally, it remains uncertain whether our observations are applicable only to human IPF or also to other forms of progressive lung fibrosis.

**Acknowledgements**

Supported by NC3Rs (NC/V002384/1), the Medical Research Council (MR/S025480/1), the Wellcome Trust (100638/Z/12/Z), an Academy of Medical Sciences/the Wellcome Trust Springboard Award [SBF002\1038], and the AAIR Charity. Infrastructure support was provided by the National Institute for Health Research (NIHR) Southampton Respiratory Biomedical Research Centre.  Graphical abstract was created with BioRender.com. We thank the staff of the NIHR Wellcome Trust Southampton Clinical Research Facility, the Biomedical Imaging Unit, and the Histochemistry Research Unit. We thank Julian Downward (The Francis Crick Institute, UK) for providing human ATII cells.

**Author contributions**

ME, JB, DD, GM, EO, MGJ conceived and designed the study. ME, JB, ERD performed all experiments and data analysis. DJ supported confocal imaging studies. YW and ZX supported in vitro studies. AF pathology review and interpretation; SJ, SVF, AA, BM tissue collection. All authors read and approved the manuscript.

**Declaration of interests**

D.E.D is co-founder of, share-holder in and consultant to Synairgen Research Ltd. D.E.D., M.G.J, and Y.W. acknowledge grants from Boehringer Ingelheim.

**FIGURE LEGENDS**

**Figure 1.** **Overview of study and analytical workflow pathway**. (A) Schematic showing workflow. (B) Overview of IPF tissue stained for pan-cytokeratin, CD45 and nuclei with areas containing regions of interest highlighted. (C-E) Insets from B showing different ROIs. Border colours denote area of B taken from, with subsequent haematoxylin and eosin (H&E) staining of the tissue section used for DSP. (F) Control lung tissue with areas containing ROIs highlighted. (G-H) Insets from F showing ROIs from control lung tissue, with corresponding H&E staining.

**Figure 2. Distinct gene expression signatures in spatially resolved regions of lung tissue.** (A) t-stochastic nearest neighbour embedding (t-SNE) dimensional reduction plot of each region of interest (ROI). (B-F) Violin plots of gene expression values of cell population marker genes. Statistical comparisons are relative to control alveolar septae. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p<0.0001 by Wilcoxon test with Benjamini-Hochberg multiple test correction. (G) Heatmap showing differentially expressed genes (as measured by a Kruskal-Wallis test (p < 0.05) across dataset, showing clustering of different ROI groups. (H-K) Bubble plots for control and IPF ROIs showing scaled enrichment scores for (H) Signalling Pathways gene sets (I) Immune regulation gene sets (J) Cell processes gene sets (K) Metabolism gene sets.

**Figure 3. Spatially resolved cell populations in lung fibrosis and control lung tissue.** (A) Bubble plot showing proportion of cell types in each ROI calculated by spatial deconvolution; (B-E) Proportions of epithelial, endothelial, immune and mesenchymal cell populations in different ROIs. Representative H&E images are higher magnification of regions visualised in Figure 1. Scale bars are 100µm.

**Figure 4. Gene expression within fibroblast foci.** A. Heatmap showing top differentially expressed genes between IPF fibroblastic foci and all other ROIs. (B) *TNC* expression (C) *CRABP2* expression (D) *COL1A2* expression. (E) *COMP* expression (F) Collagen fibril organisation GSVA scores. (G) *COL4A3* expression (H) Bone morphogenesis GSVA scores. (I) *PLOD2* expression (J) *RUNX1* expression. Statistical comparisons are relative to control alveolar septae. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p<0.0001 by Wilcoxon test with Benjamini-Hochberg multiple test correction. (K) Representative multiplexed RNA *in situ* hybridization for *COMP, COL1A2 and CRABP2* expression with a fibroblastic focus identified by \*, with the corresponding fibroblast focus (\*) identified by H&E staining on the same tissue section. Scale bar is 100µm. Inset scale bar is 50µm.

**Figure 5. Ligand-receptor interactions within the fibrotic niche.** (A) Representative H&E stained IPF lung tissue section of a fibroblast focus, immune infiltrate, and adjacent alveolar septae within the fibrotic niche following digital spatial profiling. Scale bar is 100µm. (B) Schematic of NicheNet workflow. Nichenet predicts communications based on ligand expression in sender regions, receptor expression in receiver regions, and signalling within the sender regions. (C) Pearson correlation coefficients of ligands and target genes in adjacent ROIs. (D) Dotblot showing mean ligand expression in different ROIs. (E) Regulatory potential of predicted target genes in IPF fibroblastic foci. F) Receptors expressed within fibrotic foci regions that can potentially bind to ligands found in C. Heatmap shows the regulatory potential for ligand-receptor pairs based on prior interaction knowledge. G) Results from C-E summarized in a circus plot. Arrow transparency indicates regulatory potential between ligand and target gene. Arrows are coloured depending on the region the ligand is most highly expressed in.

**Figure 6. Gene expression within immune infiltrates.** (A) Heatmap showing top differentially expressed genes between IPF immune infiltrates and all other ROIs. (B) Immunofluoresent staining (pan-cytokeratin, CD45 and nuclei) of IPF tissue with an immune infiltrate ROI highlighted. Scale bar is 100µm.(C,D). Gene expression in ROIs for *CD48* (C) and *MS4A1* (D). (E-H). Gene set variation analysis (GSVA) scores for ROIs for GO CD4 RECEPTOR BINDING (E), GO REGULATION OF ADAPTIVE IMMUNE RESPONSE (F), GO ACUTE INFLAMMATORY RESPONSE (G), HALLMARK TNFA SIGNALING VIA NFKB (H). (I-J) Expression in ROIs for *CXCR4* (I) and *CXCL12* (J). Statistical comparisons are relative to control alveolar septae. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p<0.0001 by Wilcoxon test with Benjamini-Hochberg multiple test correction.

**Figure 7. Loss of NFKBIZ dysregulates the IL-6 axis.** (A,B) GSVA scores for TGFb or WNT signalling as indicated for different ROIs. (C) Expression in ROIs for *SOD2*. (D) GSVA scores for different ROIs for Hallmark interferon alpha response. (E,F) Expression in ROIs for *NFKBIZ* (E) and *GADD45B* (F). (G) GSVA scores for different ROIs for GO RESPONSE TO INTERLEUKIN 6. (H) Expression in ROIs for *IL6.* (I-K). Expression of *NFKBIZ* (I), *IL6* (J), and *GADD45B* (K) in GSE32537. (L-N) Expression of *NFKBIZ* (L), *IL6* (M), and *GADD45B* (N) in GSE169500. Statistical comparisons are relative to control alveolar septae. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p<0.0001 by Wilcoxon test with Benjamini-Hochberg multiple test correction. (O) Representative multiplexed RNA *in situ* hybridization for *SFTPC and NFKBIZ* expression in control alveolar septae and IPF distal alveolar septae. Scale bar is 100µm and inset scale bar is 10µm (P-R) Type 2 alveolar epithelial cells were treated with TGFβ or vehicle control as indicated for 24hrs. Relative gene expression of *NFKBIZ* (P), *IL6* (Q) and *GADD45B* (R) determined by qRT-PCR and analysed using ΔΔCt method. Data are mean ±  SD; n = 7 across 3 independent experiments. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001 by 2-way ANOVA with Tukey’s multiple comparison test. (S-U) Type 2 alveolar epithelial cells were transfected with NFKBIZ targeting siRNA or control siRNA for 48hrs followed by treatment for 24hrs with TGFβ or vehicle control as indicated. (S) Relative gene expression of *IL6* measured as in (Q) (T) IL-6 protein in conditioned media quantified by ELISA. (U) Relative gene expression of *GADD45B* measured as in (T). Data are mean  ±  SD; n = 6 across 3 independent experiments.\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p<0.0001 by 2-way ANOVA with Tukey’s multiple comparison test.

# **STAR★Methods**

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Dr Mark Jones, mark.jones@soton.ac.uk

**Materials availability**

This study did not generate new unique reagents.

**Data and code availability**

All data generated during this study are included in the manuscript and supporting files. This paper also analyzes existing, publicly available data. The accession numbers for the datasets are listed in the key resources table. The public processed IPF single-cell data from Habermann et al. (GSE135893) can also be accessed via the IPF cell atlas portal at http://www.ipfcellatlas.com. The public processed healthy lung single-cell data for NFKBIZ expression can be accessed via the Human Protein Atlas, v21.proteinatlas.org: https://www.proteinatlas.org/ENSG00000144802-NFKBIZ/celltype/lung. The public healthy lung tissue staining for IκBζ can be accessed via the Human Protein Atlas, v21.proteinatlas.org: [https://www.proteinatlas.org/ENSG00000144802-NFKBIZ/tissue/lung#](https://www.proteinatlas.org/ENSG00000144802-NFKBIZ/tissue/lung).

All original code is available in this paper’s supplemental information in supporting file 1. Any additional information required to reanalyze the data

reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

Clinically indicated diagnostic surgical lung biopsy specimens were from patients with a subsequent multidisciplinary diagnosis of IPF (n=3) according to international consensus guidelines (Raghu et al., 2018). Specimens had been diagnosed as showing a typical usual interstitial pneumonia pattern by 2 independent histopathologists. Control lung tissue was from macroscopically normal lung (n=3) sampled remote from the cancer site in age and sex-matched patients undergoing lobectomy surgery for early-stage lung cancer. Details of the donor characteristics including age, gender, and disease status are provided in Supplementary Table S4B. Formalin fixed paraffin embedded tissue blocks had received standard processing with fixation in neutral buffered formalin for 48 hours and embedding in paraffin wax and tissue blocks had been archived for less than seven years. The study was approved by the Mid and South Buckinghamshire Local Research Ethics Committee (ref 07/H0607/73), and all subjects gave written informed consent.

The human alveolar type 2 cell line (ATIIER:KRASV12 ) was cultured in DCCM-1 (Biological Industries Ltd.) supplemented with 10% FBS (Life Technologies), 1% penicillin, 1% streptomycin and 1% L-glutamine (all from Sigma Aldrich), as previously described (Yao et al., 2021, 2019). No mycoplasma contamination was detected in the cell lines used.

**METHOD DETAILS**

## **Haematoxylin and Eosin (H&E) staining**

Tissue sections (5 µm) were dewaxed by immersing in xylene for 2x4 min and rehydrated by 2 changes in 100% ethanol followed by one wash in 95% ethanol for 20 seconds each before placing in running tap water for 1 minute. Tissues were stained with Haematoxylin 7211 (Fisher Scientific, #10034813) and counterstained with Eosin Y (Fisher Scientific, #12677756) for 20 seconds. As the DSP protocol is non-destructive, tissue sections can be stained with H&E once the DSP protocol is complete by placing sections in dH2O before immersing slides in Haematoxylin and following the remaining protocol as standard.

**IκBζ immunohistochemistry**

Control or IPF lung tissues (n = 3 donors) were fixed and embedded in paraffin wax; tissue sections (4 μm) were processed and stained as previously described (Brereton et al., 2022; Yao et al., 2019). Briefly, the tissue sections were de-waxed, rehydrated and incubated with 3% hydrogen peroxide in methanol for 10 min to block endogenous peroxidase activity before antigen retrieval (microwave EDTA pH 8). Sections were incubated at room temperature with a primary antibody against IκBζ (1:50, HPA010547, Sigma-Aldrich), followed by a biotinylated secondary antibody (1:500, Vector Laboratories Ltd., UK); antibody binding was detected using streptavidin-conjugated horse-radish peroxidase and visualised using DAB before counter- staining with Gill’s Haematoxylin. Images were acquired using an Olympus VS110 digital slide scanner.

**Immunofluoresence**

Formalin fixed, paraffin embedded (FFPE) IPF and healthy lung tissue tissue was deparaffinised before antigen retrieval (microwave citrate buffer pH 6). Tissue was incubated overnight at 4oC with an Alexa Fluor 555 conjugated anti-COMP Polyclonal Antibody, (1:100, Stratech) and a PLOD2-Specific Polyclonal antibody (1:100, Proteintech) before incubation with an Alexa Fluor 647 conjugated secondary antibody (1:250, Thermo Fisher Scientific) for 2 hours at room temperature before a 15 minute incubation with DAPI (1:500). Confocal images of representative ROIs were taken using a Leica TCS-SP8 confocal system on a Leica DMI8 inverted microscope stand.

**RNAscope HiPlex In Situ Hybridisation**

RNAscope was performed according to the manufacturer’s instructions using the following probes and reagents. Briefly, FFPE IPF and healthy lung tissue sections were deparaffinised, before fluorescently conjugated RNAscope hiplex probes (ACD Bio) against *COMP, COL1A2, CRABP2, SFTPC, SOD2* and *NFKBIZ* were hybridised and signal amplified using RNAscope Hiplex V2 (488, 550,650) reagents over multiple rounds of probe hybridisation and strippings. Confocal images of representative ROIs were taken using a Leica TCS-SP8 confocal system with ROI positions stored for relocation over multiple rounds of hybridisation, stripping and imaging and background fluorescence removed using a reference image of the same ROI without probes using RNAscope hiplex image registration software (ACD Bio).

## **Spatial transcriptomics**

## ***GeoMx Slide Processing***

For the Nanostring GeoMx CTA assay, slides were prepared according to the Leica Biosystems BOND RX FFPE RNA Slide Preparation Protocol in the GeoMx – NGS Slide Preparation User Manual (NanoString, MAN-10115-04). Morphology marker solution was created using SYTO13 (Nanostring), Pan-Cytokeratin morphology marker (Nanostring), and CD45 morphology marker (Nanostring).

## ***GeoMx DSP Instrument and ROI Selection***

Slides were loaded into the slide holder of the GeoMx DSP instrument and covered with 2 ml of buffer S. Each slide was scanned with a 20x objective with the scan parameters: 50 ms FITC/525 nm, 300 ms Cy3/568 nm, 300 ms Texas Red/615 nm. A serial section next to the one used for DSP analysis was stained with H&E and potential ROIs identified. Corresponding regions of interest (ROIs) were then selected on the DSP slide, with regions of interest identified by their morphology using pan-cytokeratin as an epithelial marker and CD45 as an immune marker. In IPF lung tissue selected ROIs were fibroblast foci (IPF-FF) and their adjacent alveolar septae (IPF-AAS), nearby immune infiltrates identified by CD45+ staining (IPF-IM), morphologically preserved alveolar septae distant from fibroblast foci (IPF-DAS), and blood vessel walls containing smooth muscle (IPF-BV). In healthy control lung tissue selected ROIs were alveolar septae (CTRL-AS) and blood vessel walls containing smooth muscle (CTRL-BV).

After the DSP protocol was complete the slides were also stained with H&E and each section was examined and ROI annotation confirmed by a lung histopathologist (A.F.). After ROIs were approved, the GeoMx DSP exposes the selected regions to UV light which photocleaves the UV cleavable barcode linked from the bound RNA probes, which are collected and deposed into separate wells in the DSP collection plate.

## ***GeoMx RNA Illumina Library Preparation***

DSP collection sample plates were dried, resuspended in nuclease-free water, and amplified using PCR according to the manufacturer’s protocol.

Following PCR amplification, the indexed libraries were pooled, harvested and washed using AMPure XP beads (Beckman Coulter) prior to elution. Sequencing library size was assessed with a High Sensitivity D1000 Screen Tape assay for TapeStation systems (Agilent Technologies) and the expected library size of ~150 bp was observed. Purified libraries were sequenced by Illumina NovaSeq SP (2x 50bp).

## ***Data Processing and QC***

The FASTQ reads from sequenced DSP library were processed by the GeoMx NGS Pipeline to convert sequencing reads into ROI counts (Nanostring, MAN-10118-03). After processing, counts were uploaded to the GeoMx DSP Data Analysis Suite (NanoString). QC steps were carried out to assess raw read threshold, percent aligned reads and sequencing saturation. The limit of quantification (LOQ) was determined as the negative probe geomean + 2x the geometric standard deviations of the negative probes. Any probes that could not be detected in at least 5% of ROIs were filtered, leaving 1086 genes from the original 1811. Raw counts were then normalized by Q3/upper quartile normalization (Bullard et al., 2010). Normalized counts were exported and processed further using R.

## ***Data Analysis***

Data analysis was performed in R (R Core Team, 2020). Graphics were produced using ggplot2 unless otherwise stated (Wickham, 2016, p. 2).

## ***T-stochastic nearest neighbour embedding***

The R package Rtsne (Krijthe, 2021) was used to generate T stochastic nearest neighbour embedding (T-SNE) embeddings. These were then plotted using ggplot2 to show how different regions of interest cluster on a dimensional reduction plot.

## ***Pearson correlation heatmap***

Pearson correlation coefficients between each ROI were generated and plotted using the pheatmap R package (Kolde, 2019).

## ***Differentially Expressed Genes***

A Wilcoxon rank sum test was used to identify differentially expressed genes between different regions of interest. P values were adjusted using Benjamini-Hochberg multiple test correction. An adjusted p-value cut-off of 0.05 and a logFC of 0.25 was used to identify differentially expressed genes. Variable genes across the whole dataset were identified by a Kruskal-Wallis test (p < 0.05) across the dataset in order to show clustering of different ROI groups by heatmap.

## ***Gene expression heatmaps***

Heatmaps were produced using the heatmap.2() function from the R package gplots (Galili, 2021). Heatmaps used by-row scaling, and ROIs were clustered using the default hierarchical clustering algorithm.

## ***Gene set variation analysis***

Gene set variation analysis was performed in R using the R package GSVA (Hänzelmann et al., 2013). The gsva() function was used to assess the enrichment of gene sets in each ROI. A Wilcoxon rank sum test with Benjamini-Hochberg multiple test correction (adjusted p value < 0.05) was then used to identify groups of ROIs with significantly enriched GSVA scores. TGFβ signalling genes used were ACTA2, COL1A1, COL3A1, CCN2, IL11, CDH2. Additional gene sets are taken from the gene ontology consortium or Molecular Signatures database Hallmark gene sets. Gene sets used in this comparison are in Table S4C

***Enrichment Plots***

To generate enrichment scores used for the pathway bubble plots each gene was assigned to a particular signalling pathway, immune regulator, metabolic or cell process according to the gene target group memberships provided by NanoString (https://nanostring.com/products/geomx-digital-spatial-profiler/geomx-rna-assays/geomx-cancer-transcriptome-atlas/). Each gene was assigned to a single group and typically the first target group listed for each gene was used. A full list of target group assignments for genes is available in Table S3. For each gene set, the mean normalized counts for all genes within that gene set in each region were taken. Mean counts were then scaled by taking the Z-Scores for all regions for each gene set. Bubble plots were then made using the ggplot2 package.

## ***Cell profile matrix***

The cell profile matrix was generated using a single cell RNA sequencing dataset of cells taken from different ILDs (interstitial lung diseases), generated by Habermann et al. (Habermann et al., 2020). Cells originating from IPF tissue and normal lung tissue were extracted, and the R package Seurat was used to generate a normalised genes x cells matrix (Hao et al., 2021). The FindAllMarkers() function in Seurat was then used to identify marker genes associated with the different types of cells identified in this study. This uses a Wilcoxon rank sum test to identify differentially expressed genes associated with different cell types. A p-value of < 0.05 and a logFC of > 2 was used to identify strongly differentially expressed marker genes. The mean expression of these marker genes was calculated, and the marker genes were cross-referenced with the GeoMX cancer transcriptomics atlas (CTA) to ensure that marker genes for each cell type were present in the CTA. This set of marker genes was then used as the cell profile matrix for spatial and reverse deconvolution.

## ***Spatial Deconvolution***

Spatial deconvolution was performed using the SpatialDecon R package(Danaher et al., 2020). The spatialdecon() function was used to deconvolute the bulk gene expression data from individual regions of interest into the proportions of different cell types associated with each ROI. Normalised gene expression values from the GeoMX DSP were input as the expression matrix, and the cell profile matrix described above was used for the markers. Background values were derived from the negative probe expression values. With these inputs, the spatialdecon() function outputs the relative proportions of each cell type identified in the cell profile matrix.

***Ligand-receptor Analyses***

Potential Ligand-receptor interactions were determined using the R package NicheNet (Browaeys et al, 2020). Gene counts were thresholded such that a gene was considered not to be expressed within a given ROI if it was below the negative control probe counts and all genes present in the DSP dataset were used as background genes. NicheNet infers ligand-receptor interactions by determining ligands expressed in sender regions (Immune and adjacent alveolar ROIs), receptors expressed in receiver regions (fibroblastic foci), and signalling within receiver regions. The ligand-receptor pairs most likely to induce expression of a fibrotic foci specific genes were then determined using a Pearson score cut-off of 0.1. NicheNet results were then cross referenced with results obtained using the Celllinker web server (Zhang et al., 2021), which predicts all Ligand/Receptor pairs based on the presence of these ligands and receptors within populations. Thresholded ROI counts were also used for this analysis and a gene was considered to be expressed in a particular type of ROI if it was above the threshold in 25% of ROIs. A P-Value cut-off of 0.05 was used with 100 statistical iterations.

## **Type 2 Alveolar Cell *in vitro* Studies**

ATIIER:KRASV12 cells were transfected with the indicated siRNA oligos at a final concentration of 100 nM using RNAiMax Lipofectamine reagent (Life Technologies). After 48 h, cells were treated with TGFβ at 0, 1, or 5 ng/ml for a further 24 h prior to harvesting for analysis of mRNA expression and protein release. TGFβ1 was from PeproTech. Short interfering RNA (siRNA) oligos against *NKFBIZ* (On-target Plus *NFKBIZ* Smartpool) were purchased from Dharmacon. Sequences are available from Dharmacon, or on request. As a negative control, we used On-target Plus Non Targeting Pool siRNA (Dharmacon).

For assessment of innate immune responses, cells were treated with synthetic double stranded RNA (Polyinosinic:polycytidylic acid (poly I:C) (Invivogen) at 1 or 5 μg/ml for 24 h in the absence or presence of TGFβ (1 or 5 ng/ml). Cells were harvested for mRNA expression analysis by RT-qPCR.

## **QUANTIFICATION AND STATISTICAL ANALYSIS**

## Statistical details can also be found in the figure legends.

The details of the analysis can be found in supplementary code.

All statistical tests and graphical depictions of results were performed using R version 4.0.2 (R software Foundation), or GraphPad Prism version 9.0.1 software (GraphPad Software, La Jolla, CA). For all tests, p < 0.05 was considered statistically significant. Statistical significance on figures and supplemental figures is labeled as follow: \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, \*\*\*\*p < 0.0001.

**KEY RESOURCES TABLE – SEE FILE**

**Supplementary Item Titles**

**Table S1. Normalised Digital Spatial profiling data.** Related to Figures 2-7. Normalised gene expression data for individual regions of interest using the NanoString GeoMx CTA panel. Any probes that could not be detected in at least 5% of ROIs were filtered, leaving 1086 genes from the original 1811. Raw counts were then normalized by Q3 normalization. 60 regions of interest (control alveolar septae (n=12), IPF distant alveolar septae (n=10), IPF adjacent alveolar septae (n=10), IPF fibroblastic foci (n=10), IPF immune infiltrates (n=6), IPF blood vessels (n=6), and control blood vessels (n=6).

**Table S2. Metadata for digital spatial profiling data.** Related to Figure 2.

Metadata includes unique ROI identifiers, sample descriptors and colours used for heatmap generation.

**Table S3.** Related to Figure 2. Target group assignments for genes used to generate enrichment plots shown in Figure 2**.** The median Z-Score for all genes present in each group was used to generate the bubble plots in Figure 2.

**Table S4.** Related to Figures 2, 4, 5 and 7. (A) Differentially expressed genes between IPF adjacent alveolar septae and healthy alveolar septae ROI. (B) Tissue donor demographics, (C) Gene sets used for gene set variation analysis.

**Supplementary File 1.** Related to Figures 2-7. **R script used to perform analysis of digital spatial profiling data and generate figures.**

**REFERENCES**

Adams, T.S., Schupp, J.C., Poli, S., Ayaub, E.A., Neumark, N., Ahangari, F., Chu, S.G., Raby, B.A., DeIuliis, G., Januszyk, M., Duan, Q., Arnett, H.A., Siddiqui, A., Washko, G.R., Homer, R., Yan, X., Rosas, I.O., Kaminski, N., 2020. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Science Advances 6, eaba1983. https://doi.org/10.1126/sciadv.aba1983

Ahn, J.-H., Cho, J., Kwon, B.-E., Lee, G.-S., Yoon, S., Kang, S.G., Kim, P.-H., Kweon, M.-N., Yang, H., Vallance, B.A., Kim, Y.-I., Chang, S.-Y., Ko, H.-J., 2019. IκBζ facilitates protective immunity against Salmonella infection via Th1 differentiation and IgG production. Sci Rep 9, 8397. https://doi.org/10.1038/s41598-019-44019-3

Ali, M.N., Mori, M., Mertens, T.C.J., Siddhuraj, P., Erjefält, J.S., Önnerfjord, P., Hiemstra, P.S., Egesten, A., 2019. Osteopontin Expression in Small Airway Epithelium in Copd is Dependent on Differentiation and Confined to Subsets of Cells. Sci Rep 9, 15566. https://doi.org/10.1038/s41598-019-52208-3

Arriazu, E., Ge, X., Leung, T.-M., Magdaleno, F., Lopategi, A., Lu, Y., Kitamura, N., Urtasun, R., Theise, N., Antoine, D.J., Nieto, N., 2017. Signalling via the osteopontin and high mobility group box-1 axis drives the fibrogenic response to liver injury. Gut 66, 1123–1137. https://doi.org/10.1136/gutjnl-2015-310752

Aspal, M., Zemans, R.L., 2020. Mechanisms of ATII-to-ATI Cell Differentiation during Lung Regeneration. Int J Mol Sci 21. https://doi.org/10.3390/ijms21093188

Azadeh, N., Limper, A.H., Carmona, E.M., Ryu, J.H., 2017. The Role of Infection in Interstitial Lung Diseases. Chest 152, 842–852. https://doi.org/10.1016/j.chest.2017.03.033

Bedke, N., Sammut, D., Green, B., Kehagia, V., Dennison, P., Jenkins, G., Tatler, A., Howarth, P.H., Holgate, S.T., Davies, D.E., 2012. Transforming Growth Factor-Beta Promotes Rhinovirus Replication in Bronchial Epithelial Cells by Suppressing the Innate Immune Response. PLOS ONE 7, e44580. https://doi.org/10.1371/journal.pone.0044580

Bertelsen, T., Ljungberg, C., Boye Kjellerup, R., Iversen, L., Johansen, C., 2017. IL-17F regulates psoriasis-associated genes through IκBζ. Exp Dermatol 26, 234–241. https://doi.org/10.1111/exd.13182

Brereton, C.J., Yao, L., Davies, E.R., Zhou, Y., Vukmirovic, M., Bell, J.A., Wang, S., Ridley, R.A., Dean, L.S., Andriotis, O.G., Conforti, F., Brewitz, L., Mohammed, S., Wallis, T., Tavassoli, A., Ewing, R.M., Alzetani, A., Marshall, B.G., Fletcher, S.V., Thurner, P.J., Fabre, A., Kaminski, N., Richeldi, L., Bhaskar, A., Schofield, C.J., Loxham, M., Davies, D.E., Wang, Y., Jones, M.G., 2022. Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis. eLife 11, e69348. https://doi.org/10.7554/eLife.69348

Browaeys, R., Saelens, W., Saeys, Y., 2020. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods 17, 159–162. https://doi.org/10.1038/s41592-019-0667-5

Bui, L.T., Winters, N.I., Chung, M.-I., Joseph, C., Gutierrez, A.J., Habermann, A.C., Adams, T.S., Schupp, J.C., Poli, S., Peter, L.M., Taylor, C.J., Blackburn, J.B., Richmond, B.W., Nicholson, A.G., Rassl, D., Wallace, W.A., Rosas, I.O., Jenkins, R.G., Kaminski, N., Kropski, J.A., Banovich, N.E., 2021. Chronic lung diseases are associated with gene expression programs favoring SARS-CoV-2 entry and severity. Nat Commun 12, 4314. https://doi.org/10.1038/s41467-021-24467-0

Bullard, J.H., Purdom, E., Hansen, K.D., Dudoit, S., 2010. Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 11, 94. https://doi.org/10.1186/1471-2105-11-94

Chen, I.X., Chauhan, V.P., Posada, J., Ng, M.R., Wu, M.W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., Jain, R.K., 2019. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A 116, 4558–4566. https://doi.org/10.1073/pnas.1815515116

Danaher, P., Kim, Y., Nelson, B., Griswold, M., Yang, Z., Piazza, E., Beechem, J.M., 2020. Advances in mixed cell deconvolution enable quantification of cell types in spatially-resolved gene expression data. https://doi.org/10.1101/2020.08.04.235168

Denney, L., Branchett, W., Gregory, L.G., Oliver, R.A., Lloyd, C.M., 2018. Epithelial-derived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal Immunol 11, 523–535. https://doi.org/10.1038/mi.2017.77

DePianto, D.J., Chandriani, S., Abbas, A.R., Jia, G., N’Diaye, E.N., Caplazi, P., Kauder, S.E., Biswas, S., Karnik, S.K., Ha, C., Modrusan, Z., Matthay, M.A., Kukreja, J., Collard, H.R., Egen, J.G., Wolters, P.J., Arron, J.R., 2015. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax 70, 48–56. https://doi.org/10.1136/thoraxjnl-2013-204596

Drake, T.M., Docherty, A.B., Harrison, E.M., Quint, J.K., Adamali, H., Agnew, S., Babu, S., Barber, C.M., Barratt, S., Bendstrup, E., Bianchi, S., Villegas, D.C., Chaudhuri, N., Chua, F., Coker, R., Chang, W., Crawshaw, A., Crowley, L.E., Dosanjh, D., Fiddler, C.A., Forrest, I.A., George, P.M., Gibbons, M.A., Groom, K., Haney, S., Hart, S.P., Heiden, E., Henry, M., Ho, L.-P., Hoyles, R.K., Hutchinson, J., Hurley, K., Jones, M., Jones, S., Kokosi, M., Kreuter, M., MacKay, L.S., Mahendran, S., Margaritopoulos, G., Molina-Molina, M., Molyneaux, P.L., O’Brien, A., O’Reilly, K., Packham, A., Parfrey, H., Poletti, V., Porter, J.C., Renzoni, E., Rivera-Ortega, P., Russell, A.-M., Saini, G., Spencer, L.G., Stella, G.M., Stone, H., Sturney, S., Thickett, D., Thillai, M., Wallis, T., Ward, K., Wells, A.U., West, A., Wickremasinghe, M., Woodhead, F., Hearson, G., Howard, L., Baillie, J.K., Openshaw, P.J.M., Semple, M.G., Stewart, I., Jenkins, R.G., ISARIC4C Investigators, 2020. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med 202, 1656–1665. https://doi.org/10.1164/rccm.202007-2794OC

Eto, A., Muta, T., Yamazaki, S., Takeshige, K., 2003. Essential roles for NF-κB and a Toll/IL-1 receptor domain-specific signal(s) in the induction of IκB-ζ. Biochemical and Biophysical Research Communications 301, 495–501. https://doi.org/10.1016/S0006-291X(02)03082-6

Feig, C., Jones, J.O., Kraman, M., Wells, R.J.B., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., Teichmann, S.A., Janowitz, T., Jodrell, D.I., Tuveson, D.A., Fearon, D.T., 2013. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A 110, 20212–20217. https://doi.org/10.1073/pnas.1320318110

Gaikwad, A.V., Eapen, M.S., McAlinden, K.D., Chia, C., Larby, J., Myers, S., Dey, S., Haug, G., Markos, J., Glanville, A.R., Sohal, S.S., 2020. Endothelial to mesenchymal transition (EndMT) and vascular remodeling in pulmonary hypertension and idiopathic pulmonary fibrosis. Expert Review of Respiratory Medicine 14, 1027–1043. https://doi.org/10.1080/17476348.2020.1795832

Galili, T., 2021. gplots.

Ghandikota, S., Sharma, M., Ediga, H.H., Madala, S.K., Jegga, A.G., 2022. Consensus Gene Co-Expression Network Analysis Identifies Novel Genes Associated with Severity of Fibrotic Lung Disease. International Journal of Molecular Sciences 23, 5447. https://doi.org/10.3390/ijms23105447

Habermann, A.C., Gutierrez, A.J., Bui, L.T., Yahn, S.L., Winters, N.I., Calvi, C.L., Peter, L., Chung, M.-I., Taylor, C.J., Jetter, C., Raju, L., Roberson, J., Ding, G., Wood, L., Sucre, J.M.S., Richmond, B.W., Serezani, A.P., McDonnell, W.J., Mallal, S.B., Bacchetta, M.J., Loyd, J.E., Shaver, C.M., Ware, L.B., Bremner, R., Walia, R., Blackwell, T.S., Banovich, N.E., Kropski, J.A., 2020. Single-cell RNA sequencing reveals profibrotic roles of distinct epithelial and mesenchymal lineages in pulmonary fibrosis. Science Advances 6, eaba1972. https://doi.org/10.1126/sciadv.aba1972

Hadjinicolaou, A.V., Nisar, M.K., Bhagat, S., Parfrey, H., Chilvers, E.R., Ostör, A.J.K., 2011. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review. Rheumatology (Oxford) 50, 2297–2305. https://doi.org/10.1093/rheumatology/ker289

Hänzelmann, S., Castelo, R., Guinney, J., 2013. GSVA: gene set variation analysis for microarray and RNA-Seq data. BMC Bioinformatics 14, 7. https://doi.org/10.1186/1471-2105-14-7

Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., Hoffman, P., Stoeckius, M., Papalexi, E., Mimitou, E.P., Jain, J., Srivastava, A., Stuart, T., Fleming, L.M., Yeung, B., Rogers, A.J., McElrath, J.M., Blish, C.A., Gottardo, R., Smibert, P., Satija, R., 2021. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587.e29. https://doi.org/10.1016/j.cell.2021.04.048

Hörber, S., Hildebrand, D.G., Lieb, W.S., Lorscheid, S., Hailfinger, S., Schulze-Osthoff, K., Essmann, F., 2016. The Atypical Inhibitor of NF-κB, IκBζ, Controls Macrophage Interleukin-10 Expression\*. Journal of Biological Chemistry 291, 12851–12861. https://doi.org/10.1074/jbc.M116.718825

Huang, Y., Oldham, J.M., Ma, S.-F., Unterman, A., Liao, S.-Y., Barros, A.J., Bonham, C.A., Kim, J.S., Vij, R., Adegunsoye, A., Strek, M.E., Molyneaux, P.L., Maher, T.M., Herazo-Maya, J.D., Kaminski, N., Moore, B.B., Martinez, F.J., Noth, I., 2021. Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. Am J Respir Crit Care Med 204, 197–208. https://doi.org/10.1164/rccm.202008-3093OC

Imperato, M.R., Cauchy, P., Obier, N., Bonifer, C., 2015. The RUNX1-PU.1 axis in the control of hematopoiesis. Int J Hematol 101, 319–329. https://doi.org/10.1007/s12185-015-1762-8

Jaffar, J., Griffiths, K., Oveissi, S., Duan, M., Foley, M., Glaspole, I., Symons, K., Organ, L., Westall, G., 2020. CXCR4+ cells are increased in lung tissue of patients with idiopathic pulmonary fibrosis. Respiratory Research 21, 221. https://doi.org/10.1186/s12931-020-01467-0

Jia, W., Wang, Z., Gao, C., Wu, J., Wu, Q., 2021. Trajectory modeling of endothelial-to-mesenchymal transition reveals galectin-3 as a mediator in pulmonary fibrosis. Cell Death Dis 12, 1–14. https://doi.org/10.1038/s41419-021-03603-0

Kida, H., Yoshida, M., Hoshino, S., Inoue, K., Yano, Y., Yanagita, M., Kumagai, T., Osaki, T., Tachibana, I., Saeki, Y., Kawase, I., 2005. Protective effect of IL-6 on alveolar epithelial cell death induced by hydrogen peroxide. Am J Physiol Lung Cell Mol Physiol 288, L342-349. https://doi.org/10.1152/ajplung.00016.2004

King Jr, T.E., Pardo, A., Selman, M., 2017. Idiopathic pulmonary fibrosis. The Lancet 378, 1949–1961. https://doi.org/10.1016/S0140-6736(11)60052-4

King, T.E., Albera, C., Bradford, W.Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P.W., Sahn, S.A., Szwarcberg, J., Thomeer, M., Valeyre, D., du Bois, R.M., INSPIRE Study Group, 2009. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 374, 222–228. https://doi.org/10.1016/S0140-6736(09)60551-1

Kolde, R., 2019. pheatmap: Pretty Heatmaps.

Krijthe, J., 2021. R wrapper for Van der Maaten’s Barnes-Hut implementation of t-Distributed Stochastic Neighbor Embedding.

Kumar, M.E., Bogard, P.E., Espinoza, F.H., Menke, D.B., Kingsley, D.M., Krasnow, M.A., 2014. Defining a mesenchymal progenitor niche at single cell resolution. Science 346, 1258810. https://doi.org/10.1126/science.1258810

Le, Thanh-Thuy T., Karmouty-Quintana, H., Melicoff, E., Le, Thanh-Truc T., Weng, T., Chen, N.-Y., Pedroza, M., Zhou, Y., Davies, J., Philip, K., Molina, J., Luo, F., George, A.T., Garcia-Morales, L.J., Bunge, R.R., Bruckner, B.A., Loebe, M., Seethamraju, H., Agarwal, S.K., Blackburn, M.R., 2014. Blockade of IL-6 Trans Signaling Attenuates Pulmonary Fibrosis. J Immunol 193, 3755–3768. https://doi.org/10.4049/jimmunol.1302470

Lee, W.J., Song, S.Y., Roh, H., Ahn, H.M., Na, Y., Kim, J., Lee, J.H., Yun, C.O., 2018. Profibrogenic effect of high-mobility group box protein-1 in human dermal fibroblasts and its excess in keloid tissues. Sci Rep 8, 8434. https://doi.org/10.1038/s41598-018-26501-6

Liebermann, D.A., Hoffman, B., 2002. Myeloid differentiation (MyD) primary response genes in hematopoiesis. Oncogene 21, 3391–3402. https://doi.org/10.1038/sj.onc.1205312

Liu, R., Liao, Y.-Z., Zhang, W., Zhou, H.-H., 2021. Relevance of Immune Infiltration and Clinical Outcomes in Pancreatic Ductal Adenocarcinoma Subtypes. Frontiers in Oncology 10, 2829. https://doi.org/10.3389/fonc.2020.575264

Liu, X., Rowan, S.C., Liang, J., Yao, C., Huang, G., Deng, N., Xie, T., Wu, D., Wang, Y., Burman, A., Parimon, T., Borok, Z., Chen, P., Parks, W.C., Hogaboam, C.M., Weigt, S.S., Belperio, J., Stripp, B.R., Noble, P.W., Jiang, D., 2021. Categorization of lung mesenchymal cells in development and fibrosis. iScience 24, 102551. https://doi.org/10.1016/j.isci.2021.102551

Matsuzaki, Y., Besnard, V., Clark, J.C., Xu, Y., Wert, S.E., Ikegami, M., Whitsett, J.A., 2008. STAT3 Regulates ABCA3 Expression and Influences Lamellar Body Formation in Alveolar Type II Cells. Am J Respir Cell Mol Biol 38, 551–558. https://doi.org/10.1165/rcmb.2007-0311OC

McGowan, S.E., Torday, J.S., 1997. The Pulmonary Lipofibroblast (lipid Interstitial Cell) and Its Contributions to Alveolar Development. Annual Review of Physiology 59, 43–62. https://doi.org/10.1146/annurev.physiol.59.1.43

Mehal, W.Z., Iredale, J., Friedman, S.L., 2011. Scraping fibrosis: Expressway to the core of fibrosis. Nat Med 17, 552–553. https://doi.org/10.1038/nm0511-552

Merritt, C.R., Ong, G.T., Church, S.E., Barker, K., Danaher, P., Geiss, G., Hoang, M., Jung, J., Liang, Y., McKay-Fleisch, J., Nguyen, K., Norgaard, Z., Sorg, K., Sprague, I., Warren, C., Warren, S., Webster, P.J., Zhou, Z., Zollinger, D.R., Dunaway, D.L., Mills, G.B., Beechem, J.M., 2020. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol 38, 586–599. https://doi.org/10.1038/s41587-020-0472-9

Miyake, T., Satoh, T., Kato, H., Matsushita, K., Kumagai, Y., Vandenbon, A., Tani, T., Muta, T., Akira, S., Takeuchi, O., 2010. IκBζ is essential for natural killer cell activation in response to IL-12 and IL-18. PNAS 107, 17680–17685. https://doi.org/10.1073/pnas.1012977107

Morse, C., Tabib, T., Sembrat, J., Buschur, K., Bittar, H.T., Valenzi, E., Jiang, Y., Kass, D.J., Gibson, K., Chen, W., Mora, A., Benos, P.V., Rojas, M., Lafyatis, R., 2019. Proliferating SPP1/MERTK-expressing macrophages in idiopathic pulmonary fibrosis. Eur Respir J 54, 1802441. https://doi.org/10.1183/13993003.02441-2018

Nuovo, G.J., Hagood, J.S., Magro, C.M., Chin, N., Kapil, R., Davis, L., Marsh, C.B., Folcik, V.A., 2012. The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis. Mod Pathol 25, 416–433. https://doi.org/10.1038/modpathol.2011.166

Peyser, R., MacDonnell, S., Gao, Y., Cheng, L., Kim, Y., Kaplan, T., Ruan, Q., Wei, Y., Ni, M., Adler, C., Zhang, W., Devalaraja-Narashimha, K., Grindley, J., Halasz, G., Morton, L., 2019. Defining the Activated Fibroblast Population in Lung Fibrosis Using Single-Cell Sequencing. Am J Respir Cell Mol Biol 61, 74–85. https://doi.org/10.1165/rcmb.2018-0313OC

Qi, Y., Xu, R., 2018. Roles of PLODs in Collagen Synthesis and Cancer Progression. Frontiers in Cell and Developmental Biology 6, 66. https://doi.org/10.3389/fcell.2018.00066

R Core Team, 2020. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria.

Raghu, G., Anstrom, Kevin D, King Jr, Talmadge, Lasky, J.A., Martinez, F.J., 2012. Prednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis. N Engl J Med 366, 1968–1977. https://doi.org/10.1056/NEJMoa1113354

Raghu, G., Brown, K.K., Costabel, U., Cottin, V., du Bois, R.M., Lasky, J.A., Thomeer, M., Utz, J.P., Khandker, R.K., McDermott, L., Fatenejad, S., 2008. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med 178, 948–955. https://doi.org/10.1164/rccm.200709-1446OC

Raghu, G., Remy-Jardin, M., Myers, J.L., Richeldi, L., Ryerson, C.J., Lederer, D.J., Behr, J., Cottin, V., Danoff, S.K., Morell, F., Flaherty, K.R., Wells, A., Martinez, F.J., Azuma, A., Bice, T.J., Bouros, D., Brown, K.K., Collard, H.R., Duggal, A., Galvin, L., Inoue, Y., Jenkins, R.G., Johkoh, T., Kazerooni, E.A., Kitaichi, M., Knight, S.L., Mansour, G., Nicholson, A.G., Pipavath, S.N.J., Buendía-Roldán, I., Selman, M., Travis, W.D., Walsh, S.L.F., Wilson, K.C., 2018. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 198, e44–e68. https://doi.org/10.1164/rccm.201807-1255ST

Raghu, G., Weycker, D., Edelsberg, J., Bradford, W.Z., Oster, G., 2006. Incidence and Prevalence of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine 174, 810–816. https://doi.org/10.1164/rccm.200602-163OC

Reyfman, P.A., Walter, J.M., Joshi, N., Anekalla, K.R., McQuattie-Pimentel, A.C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., Verma, R., Abdala-Valencia, H., Nam, K., Chi, M., Han, S., Gonzalez-Gonzalez, F.J., Soberanes, S., Watanabe, S., Williams, K.J.N., Flozak, A.S., Nicholson, T.T., Morgan, V.K., Winter, D.R., Hinchcliff, M., Hrusch, C.L., Guzy, R.D., Bonham, C.A., Sperling, A.I., Bag, R., Hamanaka, R.B., Mutlu, G.M., Yeldandi, A.V., Marshall, S.A., Shilatifard, A., Amaral, L.A.N., Perlman, H., Sznajder, J.I., Argento, A.C., Gillespie, C.T., Dematte, J., Jain, M., Singer, B.D., Ridge, K.M., Lam, A.P., Bharat, A., Bhorade, S.M., Gottardi, C.J., Budinger, G.R.S., Misharin, A.V., 2019. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. Am J Respir Crit Care Med 199, 1517–1536. https://doi.org/10.1164/rccm.201712-2410OC

Richeldi, L., Collard, H.R., Jones, M.G., 2017. Idiopathic pulmonary fibrosis. The Lancet 389, 1941–1952. https://doi.org/10.1016/S0140-6736(17)30866-8

Salvador, J.M., Brown-Clay, J.D., Fornace, A.J., 2013. Gadd45 in stress signaling, cell cycle control, and apoptosis. Adv Exp Med Biol 793, 1–19. https://doi.org/10.1007/978-1-4614-8289-5\_1

Seager, R.J., Hajal, C., Spill, F., Kamm, R.D., Zaman, M.H., 2017. Dynamic interplay between tumour, stroma and immune system can drive or prevent tumour progression. Converg. Sci. Phys. Oncol. 3, 034002. https://doi.org/10.1088/2057-1739/aa7e86

Selman, M., Pardo, A., 2002. Idiopathic pulmonary fibrosis: an epithelial/fibroblastic cross-talk disorder. Respir Res 3, 3. https://doi.org/10.1186/rr175

Selman, M., Pardo, A., Kaminski, N., 2008. Idiopathic Pulmonary Fibrosis: Aberrant Recapitulation of Developmental Programs? PLoS Med 5, e62. https://doi.org/10.1371/journal.pmed.0050062

Shaykhiev, R., 2019. Basal-like Cells in the BAL Fluid: An Echo of Regenerative Crisis in Idiopathic Pulmonary Fibrosis Lungs. Am J Respir Crit Care Med 199, 555–557. https://doi.org/10.1164/rccm.201808-1557ED

Song, H.-R., Lee, K.-S., Li, Q.-W., Koo, S.K., Jung, S.-C., 2003. Identification of cartilage oligomeric matrix protein (COMP) gene mutations in patients with pseudoachondroplasia and multiple epiphyseal dysplasia. J Hum Genet 48, 222–225. https://doi.org/10.1007/s10038-003-0013-7

Tang, C.-Y., Wu, M., Zhao, D., Edwards, D., McVicar, A., Luo, Y., Zhu, G., Wang, Y., Zhou, H.-D., Chen, W., Li, Y.-P., 2021. Runx1 is a central regulator of osteogenesis for bone homeostasis by orchestrating BMP and WNT signaling pathways. PLoS Genet 17, e1009233. https://doi.org/10.1371/journal.pgen.1009233

Touma, M., Keskin, D.B., Shiroki, F., Saito, I., Koyasu, S., Reinherz, E.L., Clayton, L.K., 2011. Impaired B cell development and function in the absence of IkappaBNS. J Immunol 187, 3942–3952. https://doi.org/10.4049/jimmunol.1002109

Tsukui, T., Sun, K.-H., Wetter, J.B., Wilson-Kanamori, J.R., Hazelwood, L.A., Henderson, N.C., Adams, T.S., Schupp, J.C., Poli, S.D., Rosas, I.O., Kaminski, N., Matthay, M.A., Wolters, P.J., Sheppard, D., 2020. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat Commun 11, 1920. https://doi.org/10.1038/s41467-020-15647-5

Uhlén, M., Fagerberg, L., Hallström, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., Olsson, I., Edlund, K., Lundberg, E., Navani, S., Szigyarto, C.A.-K., Odeberg, J., Djureinovic, D., Takanen, J.O., Hober, S., Alm, T., Edqvist, P.-H., Berling, H., Tegel, H., Mulder, J., Rockberg, J., Nilsson, P., Schwenk, J.M., Hamsten, M., von Feilitzen, K., Forsberg, M., Persson, L., Johansson, F., Zwahlen, M., von Heijne, G., Nielsen, J., Pontén, F., 2015. Tissue-based map of the human proteome. Science 347, 1260419. https://doi.org/10.1126/science.1260419

Vukmirovic, M., Kaminski, N., 2018. Impact of Transcriptomics on Our Understanding of Pulmonary Fibrosis. Front Med (Lausanne) 5. https://doi.org/10.3389/fmed.2018.00087

Wickham, H., 2016. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York.

Xie, N., Tan, Z., Banerjee, S., Cui, H., Ge, J., Liu, R.-M., Bernard, K., Thannickal, V.J., Liu, G., 2015. Glycolytic Reprogramming in Myofibroblast Differentiation and Lung Fibrosis. Am J Respir Crit Care Med 192, 1462–1474. https://doi.org/10.1164/rccm.201504-0780OC

Xie, T., Wang, Y., Deng, N., Huang, G., Taghavifar, F., Geng, Y., Liu, N., Kulur, V., Yao, C., Chen, P., Liu, Z., Stripp, B., Tang, J., Liang, J., Noble, P.W., Jiang, D., 2018. Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis. Cell Rep 22, 3625–3640. https://doi.org/10.1016/j.celrep.2018.03.010

Xu, Y., Mizuno, T., Sridharan, A., Du, Y., Guo, M., Tang, J., Wikenheiser-Brokamp, K.A., Perl, A.-K.T., Funari, V.A., Gokey, J.J., Stripp, B.R., Whitsett, J.A., 2016. Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis. JCI Insight 1, e90558. https://doi.org/10.1172/jci.insight.90558

Yamamoto, M., Yamazaki, S., Uematsu, S., Sato, S., Hemmi, H., Hoshino, K., Kaisho, T., Kuwata, H., Takeuchi, O., Takeshige, K., Saitoh, T., Yamaoka, S., Yamamoto, N., Yamamoto, S., Muta, T., Takeda, K., Akira, S., 2004. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IκBζ. Nature 430, 218–222. https://doi.org/10.1038/nature02738

Yang, I.V., Coldren, C.D., Leach, S.M., Seibold, M.A., Murphy, E., Lin, J., Rosen, R., Neidermyer, A.J., McKean, D.F., Groshong, S.D., Cool, C., Cosgrove, G.P., Lynch, D.A., Brown, K.K., Schwarz, M.I., Fingerlin, T.E., Schwartz, D.A., 2013. Expression of cilium-associated genes defines novel molecular subtypes of idiopathic pulmonary fibrosis. Thorax 68, 1114–1121. https://doi.org/10.1136/thoraxjnl-2012-202943

Yao, L., Conforti, F., Hill, C., Bell, J., Drawater, L., Li, J., Liu, D., Xiong, H., Alzetani, A., Chee, S.J., Marshall, B.G., Fletcher, S.V., Hancock, D., Coldwell, M., Yuan, X., Ottensmeier, C.H., Downward, J., Collins, J.E., Ewing, R.M., Richeldi, L., Skipp, P., Jones, M.G., Davies, D.E., Wang, Y., 2019. Paracrine signalling during ZEB1-mediated epithelial–mesenchymal transition augments local myofibroblast differentiation in lung fibrosis. Cell Death & Differentiation 26, 943–957. https://doi.org/10.1038/s41418-018-0175-7

Yao, L., Zhou, Y., Li, J., Wickens, L., Conforti, F., Rattu, A., Ibrahim, F.M., Alzetani, A., Marshall, B.G., Fletcher, S.V., Hancock, D., Wallis, T., Downward, J., Ewing, R.M., Richeldi, L., Skipp, P., Davies, D.E., Jones, M.G., Wang, Y., 2021. Bidirectional epithelial-mesenchymal crosstalk provides self-sustaining profibrotic signals in pulmonary fibrosis. J Biol Chem 297, 101096. https://doi.org/10.1016/j.jbc.2021.101096

Zepp, J.A., Zacharias, W.J., Frank, D.B., Cavanaugh, C.A., Zhou, S., Morley, M.P., Morrisey, E.E., 2017. Distinct mesenchymal lineages and niches promote epithelial self-renewal and myofibrogenesis in the lung. Cell 170, 1134-1148.e10. https://doi.org/10.1016/j.cell.2017.07.034

Zhang, Y., Liu, T., Wang, J., Zou, B., Li, L., Yao, L., Chen, K., Ning, L., Wu, B., Zhao, X., Wang, D., 2021. Cellinker: a platform of ligand–receptor interactions for intercellular communication analysis. Bioinformatics btab036. https://doi.org/10.1093/bioinformatics/btab036